Last updated: May 26, 2026
DEXRAZOXANE HYDROCHLORIDE Suppliers: Who Makes the API and Contract Manufacturing Options
Dexrazoxane hydrochloride is a specialized oncology and supportive-care active pharmaceutical ingredient (API) with limited, regulated supplier sets. Suppliers typically fall into four buckets: (1) API manufacturers, (2) intermediate suppliers that produce key building blocks (not always disclosed publicly), (3) contract manufacturing organizations (CMOs) for drug product (injectables) that require validated aseptic capabilities, and (4) branded/authorized distributors that source from approved API makers.
What matters operationally: dexrazoxane hydrochloride drug product supply is constrained by (a) sterile injectable manufacturing capacity, (b) API crystallization/solvates and impurity control, and (c) country-specific import licensing and batch release capacity. For licensing, litigation, and procurement planning, the highest-value supplier intelligence is Orange Book-linked and FDA-registered manufacturing site data tied to NDA/ANDA/DMF references and inspection history.
Which companies supply dexrazoxane hydrochloride API for the injectable market?
Featured snippet answer: Dexrazoxane hydrochloride API is supplied by a small number of DMF-linked API manufacturers and regional chemical producers that support sterile injectable drug products through CMO networks or direct supply agreements. Public visibility is highest via FDA DMF references and manufacturing site listings rather than retail distributor catalogs.
API supply structure in practice
- DMF manufacturers: Companies submit Drug Master Files for the dexrazoxane hydrochloride API. Drug product applicants typically reference these DMFs to qualify their supply chain for commercial batches.
- Intermediates and custom synthesis: Some suppliers focus on proprietary synthetic intermediates and sell API after finished-product crystallization and salt formation.
- Authorized distributors: Distributors typically do not synthesize API; they distribute from approved manufacturers and handle import, labeling, and chain-of-custody documentation.
Procurement signals to map suppliers
- FDA Drug Master File (DMF) holders for dexrazoxane hydrochloride.
- FDA facility registration and inspection history tied to finished sterile injectables.
- Supplier claims aligned with common injectable standards: aseptic fill-finish, batch record compliance, and validation of container closure systems.
What contract manufacturing organizations (CMOs) make dexrazoxane hydrochloride sterile injectable drug product?
Featured snippet answer: CMOs producing dexrazoxane hydrochloride typically operate sterile injectable lines with validated aseptic processing, freeze/thaw stability controls (where relevant to presentation), and strong impurity control for highly regulated oncology supportive-care products.
CMO capabilities that govern feasibility
- Aseptic manufacturing: parenteral filtration, cleanroom classification, and aseptic process validation
- Analytical method transfer: HPLC impurity profiling, potency assays, residual solvent testing if relevant to the synthetic route
- Container closure compatibility: solubility and adsorption checks for specific vial materials
- Packaging and labeling: US and EU parenteral labeling formats, controlled distribution
How to evaluate CMO fit quickly
- Track record with sterile oncology injectables (not just “injectables” generally).
- Ability to handle small-batch campaigns typical of niche supportive-care products.
- QA documentation maturity for regulatory submissions (comparability, bridging, and stability packages).
Which distributors supply dexrazoxane hydrochloride for pharmacies and hospitals?
Featured snippet answer: Distributors generally source dexrazoxane hydrochloride from licensed US/EU supply chains and sell through hospital group purchasing organizations and pharmacy wholesalers. For procurement reliability, buyers focus on distributor stock rotation, cold-chain practices where applicable, and allocation policies during API shortages.
Distributor due diligence checklist
- Product traceability from batch-level documentation to manufacturer.
- Allocation transparency during supply interruptions.
- Ability to support returns, recalls, and batch verification.
How do dexrazoxane hydrochloride supply constraints affect availability and pricing?
Featured snippet answer: Supply constraints are driven less by general “chemical commodity” availability and more by (1) the small number of qualified API producers, (2) sterile injectable fill-finish capacity, and (3) regulatory batch release throughput.
Common disruption pathways
- DMF-linked API producer capacity limitations
- Regulatory observation risk at sterile fill-finish facilities
- Import delays and customs holds for specialized sterile injectable lines
- Batch failures tied to impurity thresholds or sterility assurance testing
Procurement impact
- Longer lead times for contract batches
- Higher safety stock requirements for distributors
- Potential for partial allocations during peak demand cycles
Where do supplier lists for dexrazoxane hydrochloride come from (FDA and regulatory sources)?
Featured snippet answer: The most defensible supplier identification comes from FDA-linked entries: DMF holders, NDA/ANDA manufacturing site listings, and facility registrations. Public supplier websites are not sufficient for compliance-grade mapping.
Regulatory sources typically used in supplier mapping
- FDA Drug Master File (DMF) listings for API chemical data
- FDA NDA drug product manufacturing sites for sterile injectable drug release
- FDA facility registration and inspection histories
- BLA/ANDA databases where applicable (for branded or generic equivalents)
Are there multiple grades or forms of dexrazoxane hydrochloride suppliers (API spec, particle size, hydrate)?
Featured snippet answer: Dexrazoxane hydrochloride supplier differences usually show up in quality attributes rather than basic identity: impurity profiles, polymorphic/crystal form control, particle size distribution, and sterility-ready compatibility for sterile injectable processes.
Attributes that can change procurement terms
- Impurity thresholds and specified reporting substances
- Crystallization method producing consistent form and dissolution behavior
- Trace solvent and residual metal controls
- Stability under long-term storage and during sterile fill-finish
What patent estate and exclusivity considerations affect dexrazoxane hydrochloride supply and generic entry risks?
This section cannot be completed from the information provided.
Key Takeaways
- Dexrazoxane hydrochloride supply is structurally constrained by API qualification and sterile injectable manufacturing capacity.
- Procurement-grade supplier mapping is strongest using FDA DMF-linked API holders and FDA-registered sterile injectable manufacturing sites, not generic chemical supplier directories.
- Availability and pricing are primarily sensitive to regulatory batch release throughput and aseptic fill-finish capacity, not raw material commodity pricing alone.
- Supplier selection should prioritize compliance documentation: impurity profile consistency, analytical method transfer readiness, and validated sterile process compatibility.
FAQs
- How can a buyer verify whether a dexrazoxane hydrochloride supplier is DMF-linked for regulatory submissions?
- What sterile injectable CMO qualifications matter most for dexrazoxane hydrochloride manufacturing?
- What documentation should be requested for dexrazoxane hydrochloride API lot release and traceability?
- How do polymorph or particle-size differences in dexrazoxane hydrochloride affect formulation and stability?
- What lead-time buffers are typical for dexrazoxane hydrochloride when API supply is limited?
References
No sources were provided in the prompt, so no citations can be generated.
